Brief: GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC Filing
08/12/2025 13:14
Dec 8 (Reuters) - GRI Bio Inc GRI.O: GRI BIO INC - RECEIVES TOPLINE DATA FROM PHASE 2A TRIAL FOR IDIOPATHIC PULMONARY FIBROSIS - SEC FILING GRI BIO INC - TRIAL MEETS PRIMARY ENDPOINT & CERTAIN SECONDARY ENDPOINTS; GRI-0621 WELL TOLERATED - SEC FILING GRI BIO INC - NO SAFETY OR TOLERABILITY CONCERNS IN GRI-0621 TREATED SUBJECTS - SEC FILING Source text: [ID:n0001824293-25-000160] Further company coverage: GRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027